Navigation Links
Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idec's Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
Date:9/3/2013

predecessor compounds.

The report also finds that novel late-stage emerging disease-modifying therapies (DMTs) for the treatment of MS—Genzyme/Bayer HealthCare's Lemtrada, Biogen Idec/AbbVie's daclizumab and Roche/Genentech's ocrelizumab—will generally be reserved for treatment-refractory patients, likely reflecting safety concerns about each. Furthermore, while surveyed MCO PDs/MDs anticipate formulary coverage of these DMTs on their commercial plans broadly similar to their coverage of existing DMTs, the new entrants are more likely to be subject to indications restrictions than current DMTs and emerging reformulations.

"As more DMTs enter the MS market in the U.S., uptake and coverage of each agent will depend on clear demonstration of its value to stakeholders, driven in particular by the balance of cost, advancements in efficacy and acceptable safety," said Decision Resources Senior Director Jonathan Searles. "Moreover, MCO PDs/MDs indicate that post-marketing studies supporting the health economic benefits of a DMT will be an influential factor in determining future formulary coverage—as a result, generating compelling evidence of pharmacoeconomic benefit represents an important potential opportunity for nonclinical differentiation."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resourc
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
2. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
3. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
4. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
5. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
6. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
7. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
8. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
9. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
10. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
11. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... -- Houston dentist , Dr. Behzad Nazari ... Invisalign. With access to this increasingly popular orthodontic ... without feeling self-conscious in the process. Invisalign offers ... of braces, but patients who choose Invisalign over ... support for their oral health and comfort during ...
(Date:7/28/2014)... ORLANDO, Fla. , July 28, 2014 /PRNewswire/ ... "Company"), a biopharmaceutical company focused on the development, ... that it has filed definitive proxy materials with ... its 2014 Annual Meeting of Shareholders to be ... a.m., East Standard Time. The record date for ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3
... Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences ... clinical,trial showing that KOS-1584/R1645, an epothilone under,co-development ... in patients with solid tumors.,KOS-1584/R1645 showed activity ... including activity in patients with non-small cell ...
... Investigational cancer drug Pertuzumab shows promising results ... Phase III,development initiated, BASEL, Switzerland, June 4, ... exciting new cancer medicine pertuzumab, a HER,dimerisation ... pre-treated HER2 positive breast cancer, when,combined with ...
Cached Medicine Technology:Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 2Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 3Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 4Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 5Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5
(Date:7/28/2014)... TN (PRWEB) July 28, 2014 ... Operation Military June . Renowned LASIK and ... June" to provide significant funds and public awareness ... and retired military personnel and their families. “This ... will proudly give nearly $5,000 to a variety ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Cape ... Summit Provider Exchange technology solution in an ... efforts and support collaboration with their New Jersey ... acute-care medical center located in New Jersey, serves ... visitors with a variety of inpatient and outpatient ...
(Date:7/28/2014)... Maureen Salamon ... News) -- Infants and children who are at risk ... be vaccinated against the infection, according to updated recommendations ... And routine vaccinations for the potentially deadly ... American Academy of Pediatrics says. In its first ...
(Date:7/28/2014)... researchers report that an alternative to the traditional handshake ... experiments, the scientists found that clasping hands transferred about ... other than what is known as a fist bump. ... a cultural substitute for the firm gripping of hands. ... of the American Journal of Infection Control . ...
(Date:7/28/2014)... Reinberg HealthDay Reporter MONDAY, ... and heart rhythm irregularities are more likely to get a ... In fact, the study of more than 16,000 people found ... likely to get a pacemaker than those without the memory-robbing ... why folks with dementia are so much more likely to ...
Breaking Medicine News(10 mins):Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3
... MEMPHIS, Tenn., Oct. 21 Sedgwick Claims Management ... compliance services as an in-house, integrated program option ... clients. The Sedgwick CMS Medicare solution includes ... and resolution, and related consulting services. The ...
... , NEW YORK, Oct. 21 The Nielsen Company ... CLIO Awards , one of the world,s most ... of finalists for the first-ever CLIO Healthcare Awards ... Healthcare Awards taking place on November 13 at Skyline ...
... 21, 2009) The International Serious Adverse Events Consortium ... Research Network (HMORN) to improve the safe use of ... individuals makes them more likely to experience serious drug-related ... non-profit international research consortium. The HMORN is the ...
... issues of sexual dysfunction with their patients, according to ... In their article appearing in a November 2009 ... Internal Medicine , now available online, the investigators report ... survey indicated they rarely or never discussed sexual problems ...
... ... the right gift basket., , ... CA (PRWEB) October 21, 2009 -- For all those times when the words ,thank you, ... baskets that send the right message, at the right time and for the right price. ...
... Plastic Surgeons ... ... Surgeons (ASPS) will donate more than 1,500 multi-sport helmets to the children of Seattle in ... held at Leschi Elementary School in Seattle during an assembly in which the children will ...
Cached Medicine News:Health News:Sedgwick CMS Integrates Medicare Compliance Solution With Claims Management Services 2Health News:Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards 2Health News:Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards 3Health News:Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards 4Health News:Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards 5Health News:Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards 6Health News:Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards 7Health News:Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards 8Health News:Research partnership will study how electronic medical records can address genetics of drug safety 2Health News:Sexual problems rarely addressed by internists caring for cancer survivors 2Health News:Re-define 'Thank-You' With Style and Value From Van's Gifts 2Health News:Seattle Public Schools Get Free “Helmets 4 Safety” 2Health News:Seattle Public Schools Get Free “Helmets 4 Safety” 3Health News:Seattle Public Schools Get Free “Helmets 4 Safety” 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: